Serum zinc levels are increased in melanoma patients

Melanoma Research

Volumn 8, Issue 3, 1998, Pages 273-277

  Ros Bullon M R ^a   Sanchez Pedreno P ^b   Martinez Liarte J H ^c  

^a HUV Arrixaca

^b Division of Dermatology

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

Melanoma; Serum copper; Serum zinc; Tumour markers

Indexed keywords

COPPER; TUMOR MARKER; ZINC;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; DIAGNOSTIC ACCURACY; DISEASE MARKER; EARLY DIAGNOSIS; EQUIPMENT; HUMAN; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; ZINC BLOOD LEVEL;

COPPER; HUMANS; MELANOMA; ROC CURVE; SKIN NEOPLASMS; SPECTROPHOTOMETRY, ATOMIC; TUMOR MARKERS, BIOLOGICAL; ZINC;

EID: 0031839295     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199806000-00011     Document Type: Article

References (43)

1. Virji MA, Mercer DW, Heberman RB. Tumor markers in cancer diagnosis and prognosis. CA Cancer J Clin 1988; 38: 104-126.
2. Buzaid AC, Sandler AH, Hayden CL, et al. Correlation between lipid-associated sialic acid and tumor burden in melanoma. Int J Biol Markers 1994; 9: 247-250.
3. Finck SJ, Giuliano AE, Morton DL. LDH and melanoma. Cancer 1983; 51: 840-843.
4. Cooper EH. Neuron-specific enolase. Int J Biol Markers 1994; 9: 205-210.
5. Deffuant C, Celerier P, Boiteau HL, et al. Serum selenium in melanoma and epidermotropic cutaneous T-cell lymphoma. Acta Derm Venereol 1994; 74: 90-92.
6. Picardo M, Grammatico P, Roccella E et al. Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Invest Dermatol 1996; 107: 322-320.
7. Ito S. Melanin-related metabolites as markers of melanoma: a review. J Dermatol 1992; 19: 802-805.
8. Hara H, Walsh N, Yamada K, et al. High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a pronostic marker for malignant melanoma. J Invest Dermatol 1994; 102: 501-505.
9. Kärnell R, von Schoultz E, Hansson L-O. et al. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 1997; 7: 393-399.
10. Hirai S, Kageshita T, Kimura T, et al. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res 1997; 7: 58-62.
11. Horcicko J, Pavel S, Borovansky J, et al. Excretion of melanogens and zinc during the growth of melanoma in hamsters. Neoplasma 1979; 26: 471-475.
12. Kolaric K, Roguljic A, Fuss V. Serum copper levels in patients with solid tumors. Tumori 1975; 61: 173-177.
13. Matous B, Ciganek EF, Budesinska A, et al. Biochemical markers of malignant melanoma. Neoplasma 1987; 34: 77-84.
14. Fisher GL, Spitler LE, McNeill KL, et al. Serum copper and zinc levels in melanoma patients. Cancer 1981; 47: 1838-1844.
15. Horcicko J, Pantucek M. Hypozincemia in patients with malignant melanoma. Clin Chim Acta 1983; 130: 279-282.
16. Siu TO, Basu T, Jerry LM. Zinc, carotene, and retinol in melanoma and non melanoma skin cancer. In Vivo 1991; 5: 65-68.
17. Gorodetsky R, Sheskin J, Weinreb A. Iron, copper, and zinc concentrations in normal skin and in various nonmalignant and malignant lesions. Int J Dermatol 1986; 25: 440-445.
18. American Joint Committee on Cancer. Manual for Staging of Cancer, 3rd edn. Philadelphia: JB Lippincott, 1988: 143-148.
19. Clark WH Jr, Ainsworth AM, Bernardino EA, et al. The developmental biology of primary human malignant melanomas. Semin Oncol 1975; 2: 83-103.
20. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-908.
21. Butrimovitz GP, Purdy WC. The determination of zinc in blood plasma by atomic absorption spectrometry. Anal Chim Acta 1977; 94: 63.
22. Dawson JB, Ellis DJ, Newton-John H. Direct estimation of copper in serum and urine by atomic absorption spectroscopy. Clin Chim Acta 1968; 21: 33-37.
23. Schoonjans F, Zalata A, Depuydt CE, et al. MedCalc: a new computer program for medical statistics. Comp Methods Programs Biomed 1995; 48: 257-262.
24. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8: 283-298.
25. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.
26. Beguin Y, Brasseur F, Weber G, et al. Observations of serum trace elements in chronic lymphocytic leukemia. Cancer 1987; 60: 1842-1846.
27. Thurnham DL, Rathakette P, Hambidge KM, et al. Riboflavin, vitamin A and zinc status in Chinese subjects in a high-risk area for oesophageal cancer in China. Hum Nutr Clin Nutr 1982; 36: 337-349.
28. Lin HJ, Chan WC, Fong YY, et al. Zinc levels in serum, hair and tumors from patients with oesophageal cancer. Nutr Rep Int 1977; 15: 635-643.
29. Versieck J, Hoste J, Barbier F. Determination of manganese, copper and zinc in serum normal controls and patients with liver metastases. Acta Gastroenterol Belg 1976; 39: 340.
30. Kune GA, Kune S, Watson LF, et al. Serum levels of beta-carotene, vitamin A and zinc in male lung cancer cases and controls. Nutr Cancer 1989; 12: 169-176.
31. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
32. Hoffman SJ, Yohn JJ, Norris, DA, et al. Cutaneous malignant melanoma. Curr Probl Dermatol 1993; 5: 7-41.
33. Jiménez M, Tsukamoto K, Hearing VJ. Tyrosinases from two different loci are expressed by normal and by transformed melanocytes. J Biol Chem 1991; 266: 1141-1147.
34. Tsukamoto K, Jackson IJ, Urabe K, et al. A second tyrosinase-related protein, TRP2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J 1992; 11: 519-526.
35. Wrinkler ME, Lerch K, Solomon EI. Competitive inhibitor binding to the binuclear copper active site in tyrosinase. J Am Chem Soc 1981; 103: 7001-7003.
36. Solano F, Martínez-Liarte JH, Jiménez-Cervantes C et al. Dopachrome tautomerase is a zinc-containing enzyme. Biochem Biophys Res Commun 1994; 204: 1243-1250.
37. Solano F, Jiménez-Cervantes C, Martínez-Liarte JH, et al. Molecular mechanism for catalysis by a new zinc-enzyme, dopachrome tautomerase. Biochem J 1996; 313: 447-453.
38. Borovansky J. Zinc in pigmented cells and structures, interactions and possible roles. Sb-Lek 1994; 95: 309-320.
39. Garratt RC, Jhoti H. A molecular model for the tumor-associated antigen, p97, suggests a Zn-binding function. FEBS Lett 1992; 305: 55-61.
40. Fernandez-Pol JA. Metallopanstimulin as a novel tumor marker in sera of patients with various types of common cancers: implications for prevention and therapy. Anticancer Res 1996; 16: 2177-2185.
41. Muthukkumar S, Nair P, Sells SF, et al. Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6. Mol Cell Biol 1995; 15: 6262-6272.
42. Fornzler D, Altschmied J, Nanda Y et al. The Xmrk oncogene promoter is derived from a novel amplified locus of unusual organization. Genome Res 1996; 6: 102-113.
43. Damian DL, Halliday GM, Barnetson RS. Broad-spectrum sunscreens provide greater protection against ultraviolet-radiation-induced suppresion of contact hypersensitivity to a recall antigen in humans. J Invest Dermatol 1997; 109: 146-151.